Cargando…

The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets

The incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) mediate insulin responses that are proportionate to nutrient intake to facilitate glucose tolerance(1). The GLP-1 receptor (GLP-1R) is an established drug target for the treatment of diabetes and obe...

Descripción completa

Detalles Bibliográficos
Autores principales:	El, Kimberley, Douros, Jonathan D., Willard, Francis S., Novikoff, Aaron, Sargsyan, Ashot, Perez-Tilve, Diego, Wainscott, David B., Yang, Bin, Chen, Alex, Wothe, Donald, Coupland, Callum, Tschöp, Mattias H., Finan, Brian, D’Alessio, David A., Sloop, Kyle W., Müller, Timo D., Campbell, Jonathan E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290954/ https://www.ncbi.nlm.nih.gov/pubmed/37277609 http://dx.doi.org/10.1038/s42255-023-00811-0

Ejemplares similares

Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems
por: Yang, Bin, et al.
Publicado: (2022)

Structural determinants of dual incretin receptor agonism by tirzepatide
por: Sun, Bingfa, et al.
Publicado: (2022)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
por: Mroz, Piotr A., et al.
Publicado: (2018)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
por: Wang, Lijing
Publicado: (2022)

Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
por: Capozzi, Megan E, et al.
Publicado: (2018)

Dual GIPR and GLP-1R agonist tirzepatide inhibits aeroallergen-induced allergic airway inflammation in mouse model of obese asthma
por: Toki, Shinji, et al.
Publicado: (2023)

Temporal plasticity of insulin and incretin secretion and insulin sensitivity following sleeve gastrectomy contribute to sustained improvements in glucose control
por: Douros, Jonathan D., et al.
Publicado: (2019)

Pharmacological antagonism of the incretin system protects against diet-induced obesity
por: Svendsen, Berit, et al.
Publicado: (2019)

Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
por: Killion, Elizabeth A., et al.
Publicado: (2020)

Gipr Is Essential for Adrenocortical Steroidogenesis; However, Corticosterone Deficiency Does Not Mediate the Favorable Metabolic Phenotype of Gipr(−/−) Mice
por: Bates, Holly E., et al.
Publicado: (2012)

The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity
por: Lempesis, Ioannis G., et al.
Publicado: (2022)

Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
por: Campbell, Jonathan E.
Publicado: (2020)

GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior
por: Samms, Ricardo J., et al.
Publicado: (2022)

Effect of Glycemia on Plasma Incretins and the Incretin Effect During Oral Glucose Tolerance Test
por: Salehi, Marzieh, et al.
Publicado: (2012)

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
por: Zhang, Qian, et al.
Publicado: (2021)

Spatiotemporal regulation of GIPR signaling impacts glucose homeostasis as revealed in studies of a common GIPR variant
por: Yammine, Lucie, et al.
Publicado: (2023)

GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Basedz Therapies in Treating Metabolic Disorders
por: Samms, Ricardo J., et al.
Publicado: (2021)

Incretin Therapy and Islet Pathology: A Time for Caution
por: Kahn, Steven E.
Publicado: (2013)

Incretin-Modulated Beta Cell Energetics in Intact Islets of Langerhans
por: Hodson, David J., et al.
Publicado: (2014)

Postnatal Development of Numbers and Mean Sizes of Pancreatic Islets and Beta-Cells in Healthy Mice and GIPR(dn) Transgenic Diabetic Mice
por: Herbach, Nadja, et al.
Publicado: (2011)

Incretin-like effects of small molecule trace amine-associated receptor 1 agonists
por: Raab, Susanne, et al.
Publicado: (2015)

Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis
por: Mima, Akira, et al.
Publicado: (2023)

GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
por: El, K., et al.
Publicado: (2021)

Genetic disruption of the Gipr in Apoe(−/−) mice promotes atherosclerosis
por: Pujadas, Gemma, et al.
Publicado: (2022)

Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review
por: Liarakos, Alexandros Leonidas, et al.
Publicado: (2023)

Tirzepatide: A Systematic Update
por: Forzano, Imma, et al.
Publicado: (2022)

Adverse Events Related to Tirzepatide
por: Mishra, Rahul, et al.
Publicado: (2023)

Tirzepatide for type 2 diabetes
por: Anderson, Sarah L, et al.
Publicado: (2023)

Incretin effect of Urena lobata leaves extract on structure and function of rats islet β-cells
por: Purnomo, Y., et al.
Publicado: (2016)

Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue
por: Samms, Ricardo J., et al.
Publicado: (2022)

Reagents and models for detecting endogenous GLP1R and GIPR
por: Ast, Julia, et al.
Publicado: (2021)

Genetically proxied impaired GIPR signaling and risk of 6 cancers
por: Rogers, Miranda, et al.
Publicado: (2023)

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
por: Nauck, Michael A., et al.
Publicado: (2022)

Consequences on islet and incretin hormone responses to dinner by omission of lunch in healthy men
por: Lindgren, Ola, et al.
Publicado: (2020)

Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles
por: Bueno, Ana B., et al.
Publicado: (2016)

Advent of tirzepatide: boon for diabetic and obese?
por: Bhusal, Amrit
Publicado: (2023)

Tirzepatide and prevention of chronic kidney disease
por: Bosch, Catalina, et al.
Publicado: (2022)

Tirzepatide-Induced Injection Site Reaction
por: Mizumoto, Junki
Publicado: (2023)

The gut hormone receptor GIPR links energy availability to the control of hematopoiesis
por: Pujadas, Gemma, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lg18hdbftp7ju2b8mebdivpnqn